major breakthrough is on the horizon for Crohn's disease
December 1997
A major breakthrough is on the horizon for Crohn's disease. The drug will be called infliximab (Avakine)...by Centocor.
Crohn's is an autoimmune disease. Tumor necrosis factor (TNF) is involved. Avakine is a monoclonal antibody that blocks this factor...and slows the inflammation.
In fact, it shows dramatic improvement in two-thirds of patients with moderate to severe Crohn's. One injection gives benefits lasting several months.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote